- Home
- Automated
- List of product information
- CLARITYNE TABLET 10MG [SIN14077P]
CLARITYNE TABLET 10MG [SIN14077P]
Active ingredients: CLARITYNE TABLET 10MG
On this page
Product Info
CLARITYNE TABLET 10MG
[SIN14077P]
Product information
Active Ingredient and Strength | LORATADINE - 10 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | SCHERING-PLOUGH LABO NV - BELGIUM |
Registration Number | SIN14077P |
Licence Holder | BAYER (SOUTH EAST ASIA) PTE LTD |
Forensic Classification | GENERAL SALE LIST |
Anatomical Therapeutic Chemical (ATC) code | R06AX13 |
4.1 Therapeutic indications
CLARITYNE® Products are indicated for the relief of symptoms associated with allergic rhinitis, such as sneezing, nasal discharge (rhinorrhea) and itching, as well as ocular itching and burning. Nasal and ocular signs and symptoms are relieved rapidly after oral administration. CLARITYNE® Products are also indicated for relief of symptoms and signs of chronic urticaria and other allergic dermatologic disorders.
4.2 Posology and method of administration
Adults and Children 12 years of age and over:
CLARITYNE® Tablet: One tablet (10 mg) once daily;
Children 6 to 12 years of age:
CLARITYNE® Tablet:
Body Weight >30 kg -- One tablet (10 mg) once daily
Safety and efficacy of CLARITYNE® has not been established in children younger than 2 years of age.
Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; an initial dose of 5 mg once daily, or 10 mg every other day is recommended.
4.3 Contraindications
CLARITYNE® Products are contraindicated in patients who are hypersensitivity to the active substance or to any of the excipients in these formulations.
